Navigation Links
Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Date:11/6/2007

ORLANDO, Fla., Nov. 6 /PRNewswire/ --

What and When

Additional results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), will be presented as an oral session at the American Heart Association Scientific Sessions 2007 being held November 4 through 7, 2007 in Orlando, Florida.

Results revealed that reduced progression of carotid intima-media thickness (CIMT), the thickness of the inner lining of a patient's carotid, with ACTOS was associated with increased HDL cholesterol and decreased insulin levels when compared to glimepiride. An increase in CIMT is an indicator of atherosclerosis, a condition that leads to reduced or blocked blood flow and is a surrogate marker for the risk of heart attack and stroke.

CHICAGO is the largest and longest study to examine the effects of ACTOS on measures of the atherosclerotic disease process in patients with type 2 diabetes. The randomized, double-blind, controlled study enrolled 462 patients with type 2 diabetes. Patients were treated with a 15 to 45 mg dose of ACTOS or 1 to 4 mg dose of glimepiride for 72 weeks with evaluation after 6 months. The results from the CHICAGO study demonstrated significant improvements on cardiovascular risk markers beyond glycemic control with ACTOS.

The CHICAGO trial adds to the already substantial body of evidence regarding cardiovascular data that has been developed over several years of research on ACTOS.

Oral presentation on November 6, 2007 from

9:15 to 9:30 a.m. Eastern Standard Time

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS, a prescription medication, is taken once daily as an adjunct to diet and exercise, and is approved for use for type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas, or metformin.

Additional Information

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause or worsen congestive heart failure. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, and anemia. Some people, particularly women, are at higher risk of having bone fractures while taking ACTOS. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.

Please visit the ACTOS Web site at http://www.actos.com for Complete Prescribing Information.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral diabetes, insomnia, and gastroenterology treatments, and through the Takeda Global Research & Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease, and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.

ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or TV ... known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller ... technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
Breaking Medicine Technology:
(Date:5/3/2016)... FORT WORTH, Texas (PRWEB) , ... May 03, 2016 , ... ... some of the signs of pet anxiety. "Pet owners often think anxiety only ... be sending stress signals in other ways, and there’s things that be done about ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... online university, has announced today the launch of its Associates and Bachelor's degrees ... President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a leader ... Health, a three hospital system in South Carolina, to provide its secure mobile ... technology that enhances communication, drives workflow efficiencies and improves provider and patient satisfaction,” ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean ... launching a new client service center in La Vergne, Tennessee, near Nashville. The ... the full range of Empyrean client services. , “Our Nashville-area center allows us ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
Breaking Medicine News(10 mins):